We are excited to share that Biocytogen will be attending the LSE vendor show at Ohio State University on April 30th. We will be presenting our extensive portfolio of animal models and comprehensive preclinical pharmacology services. Visit our booth to learn how Biocytogen can help support your research studies.
What is LSE?
The Life Science Exhibits (LSE) is a premier event planning company hosting Research Supplier Product Shows across the U.S. With over 20 years of experience and more than 100 annual events, LSE connects vendors with researchers at top institutions, offering access to the latest products, reagents, and equipment.
Event Overview
Date: September 30th, 2026
Venue: Ohio State University The Faculty Club, Upper Level, 181 South Oval Drive Columbus, OH 43210
Event Schedule
For more information about the LSE vendor show, please visit their website here.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
